United Therapeutics Corp
F:UTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
U
|
United Therapeutics Corp
F:UTH
|
US |
|
U
|
United Therapeutics Corp
XMUN:UTH
|
US |
Intrinsic Value
The intrinsic value of 
United Therapeutics Corp (UTH) under the Base Case is 486.54 EUR per share.
Compared with the current market price of 521.2 EUR, the stock appears
Overvalued by 7% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What United Therapeutics Does
United Therapeutics is a biotechnology company focused on serious, long-term diseases where patients often need ongoing treatment. Its main business is making medicines for pulmonary hypertension, a condition that raises blood pressure in the lungs and can become life threatening. The company also works on organ manufacturing and transplant-related technologies, which reflects its goal of finding treatments for patients with very limited options.
- Headquarters
- United States of America US
- Employees
- 1 400
- IPO date
- Jun 17, 1999
United Therapeutics has a narrow economic moat
Patents covering key medicines and their delivery technology prevent rivals from freely copying parts of United Therapeutics’ treatments. For some Remodulin patients, changing treatment also means learning a different pump system and carefully managing an uninterrupted drug supply, making a cheaper rival less straightforward to adopt.
Read the full moat analysis
Revenue & Expenses Breakdown
United Therapeutics Corp
Earnings Waterfall
United Therapeutics Corp
The intrinsic value for United Therapeutics Corp (UTH) under the Base Case is 486.54 EUR.
Compared with the current market price of 521.2 EUR, the stock appears Overvalued by 7% .